What is a stock summary page? Click here for an overview.
Business Description
Mirum Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US6047491013
Description
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.88 | |||||
| Equity-to-Asset | 0.34 | |||||
| Debt-to-Equity | 1.41 | |||||
| Debt-to-EBITDA | -6.49 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.05 | |||||
| Beneish M-Score | -2.76 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 124 | |||||
| 3-Year EBITDA Growth Rate | 22 | |||||
| 3-Year EPS without NRI Growth Rate | 12.4 | |||||
| 3-Year FCF Growth Rate | 64.5 | |||||
| 3-Year Book Growth Rate | 5.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 22.38 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 16.47 | |||||
| 9-Day RSI | 27.84 | |||||
| 14-Day RSI | 33.89 | |||||
| 3-1 Month Momentum % | 4.93 | |||||
| 6-1 Month Momentum % | 18.99 | |||||
| 12-1 Month Momentum % | 88.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.1 | |||||
| Quick Ratio | 2.93 | |||||
| Cash Ratio | 2.22 | |||||
| Days Inventory | 96.88 | |||||
| Days Sales Outstanding | 71.55 | |||||
| Days Payable | 51.33 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.5 | |||||
| Shareholder Yield % | -4.05 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.77 | |||||
| Operating Margin % | -26 | |||||
| Net Margin % | -26.1 | |||||
| FCF Margin % | -3.2 | |||||
| ROE % | -37.58 | |||||
| ROA % | -13.33 | |||||
| ROIC % | -29.57 | |||||
| 3-Year ROIIC % | 49.56 | |||||
| ROC (Joel Greenblatt) % | -749.28 | |||||
| ROCE % | -13.2 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.46 | |||||
| PB Ratio | 9 | |||||
| Price-to-Operating-Cash-Flow | 168.12 | |||||
| EV-to-EBIT | -28.89 | |||||
| EV-to-EBITDA | -42.83 | |||||
| EV-to-Revenue | 6.23 | |||||
| EV-to-Forward-Revenue | 4.87 | |||||
| EV-to-FCF | -196.62 | |||||
| Price-to-GF-Value | 0.62 | |||||
| Earnings Yield (Greenblatt) % | -3.46 | |||||
| FCF Yield % | -0.52 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mirum Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 312.4 | ||
| EPS (TTM) (€) | -1.72 | ||
| Beta | 0.38 | ||
| 3-Year Sharpe Ratio | 0.7 | ||
| 3-Year Sortino Ratio | 1.32 | ||
| Volatility % | 49.79 | ||
| 14-Day RSI | 33.89 | ||
| 14-Day ATR (€) | 1.651223 | ||
| 20-Day SMA (€) | 41.08 | ||
| 12-1 Month Momentum % | 88.5 | ||
| 52-Week Range (€) | 21.8 - 51 | ||
| Shares Outstanding (Mil) | 49.01 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mirum Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mirum Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mirum Pharmaceuticals Inc Frequently Asked Questions
What is Mirum Pharmaceuticals Inc(FRA:08D)'s stock price today?
The current price of FRA:08D is €37.60. The 52 week high of FRA:08D is €51.00 and 52 week low is €21.80.
When is next earnings date of Mirum Pharmaceuticals Inc(FRA:08D)?
The next earnings date of Mirum Pharmaceuticals Inc(FRA:08D) is 2025-05-08 Est..
Does Mirum Pharmaceuticals Inc(FRA:08D) pay dividends? If so, how much?
Mirum Pharmaceuticals Inc(FRA:08D) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers